Key Takeaways
- Guidance held, but margin pain is real: Full-year revenue, EBITDA and PAT margin guidance maintained despite H1 EBITDA margin compressing 193 bps to 22.7%, with staff costs the primary culprit.
- Research services carried the quarter: Underlying growth in research services offset an anticipated inventory correction in biologics manufacturing, keeping the top-line story intact.
- A landmark clinical win: Syngene won its first global Phase III clinical trial contract, a U.S.-based biotech study recruiting across U.S. and Indian sites, marking a step-up in the clinical services value chain.
- Bayview is the H2 catalyst: The U.S. biologics facility remains on track for H2 FY26 operationalization, with revalidation and staff recruitment advancing; its contribution is critical to the second-half outlook.
- What to watch next quarter: Whether the Bayview timeline holds, the pace of margin recovery implied by the full-year guidance, and any conversion of the “early signs” of U.S. biotech funding improvement into concrete order book growth.
Margin & Cost Structure
- Staff costs spiked sharply: Staff costs rose 13.3% YoY to 307.5 crore, reaching 33.8% of revenue versus 30.4% a year ago, a 331 bps headwind that drove the bulk of the EBITDA margin decline.
- Forex swung to a loss: A net forex loss of 11.8 crore replaced a 4.3 crore gain in Q2 FY25, a 16.1 crore swing that compounded the cost pressure.
- Other expenses crept up: Other expenses rose to 14.1% of revenue from 13.3%, adding another 78 bps of margin drag.
- Material costs provided a partial offset: Material costs improved to 25.6% of revenue in H1 FY26 from 28.0% in H1 FY25, a 242 bps tailwind that softened but did not reverse the overall compression.
- Depreciation rose on Stelis capitalisation: Depreciation increased 5.1% YoY to 116.5 crore, partly reflecting the ₹343.8 Cr capitalisation of the Stelis Biopharma facility license.
- A one-off receivable write-off: ₹27.7 Cr gross (₹20.2 Cr after tax) was written off as unrecoverable due to cumulative foreign exchange rate changes, a non-operational item that further weighed on reported PAT.
Deepak Jain: "Our strong balance sheet and net cash position provide the financial flexibility to invest in key strategic priorities to support our growth."
Clinical Services Breakthrough
- First global Phase III trial won: Syngene secured its first contract for a global Phase III clinical trial from a U.S.-based biotech company, with patient recruitment spanning clinical sites in the U.S. and India.
- Footprint expanded aggressively: The clinical trials footprint was extended to Australia, New Zealand, the UK, Sri Lanka and Eastern Europe through strategic partnerships with established CROs, broadening the platform for future Phase III wins.
- Signalling a value-chain shift: The Phase III win moves Syngene beyond early-phase clinical work into larger, later-stage trials that carry higher revenue potential and stickier client relationships.
Biologics Manufacturing: Correction Now, Capacity Later
- Inventory correction hit manufacturing: The quarter’s biologics manufacturing revenue was dampened by an anticipated inventory correction, which research services growth fully offset at the group level.
- Bayview is the second-half swing factor: Revalidation, integration and staff recruitment at the Bayview biologics facility in the U.S. remain on track, with operationalization targeted for H2 FY26.
- Stelis facility now on the books: The acquired Stelis Biopharma facility in Bangalore received a drug substance production line license and a bonded warehouse license in Q1 FY26, with ₹343.8 Cr capitalised as property, plant and equipment.
- New modalities are being built out: A new GMP bioconjugation suite is under construction in the Bengaluru biologics facility to enable end-to-end manufacturing of Antibody Drug Conjugates (ADCs), and the company is investing in dedicated peptide facilities.
Peter Bains: "Our Q2 performance was driven by underlying revenue growth from research services which compensated for the anticipated inventory correction in biologics manufacturing. We are maintaining our annual guidance for revenue for FY26."
Demand Environment & Funding
- U.S. biotech funding shows tentative green shoots: Management noted early signs of improvement in the U.S. biotech funding environment, while cautioning that it continues to monitor trends and keep strategies agile.
- No order book quantification provided: The call offered no data on how the funding improvement is translating into RFPs, bookings or pipeline conversion, leaving the demand recovery as a directional signal rather than a quantified trend.
- Medium-term thesis rests on capacity and diversification: Management pointed to diversified service offerings and available biologics manufacturing capacity as the structural drivers that position the company for medium-to-long-term growth, independent of near-term funding cycles.
Peter Bains: "From a broader perspective, the U.S. biotech funding environment is showing early signs of improvement. We continue to monitor trends and maintain agile strategies to adapt quickly as the funding environment evolves."
Sustainability & Operational Milestones
- My Green Lab certification achieved at the highest level: The company earned ‘Green Certification’ with a score exceeding 94%, the highest tier awarded by the programme.
- EcoVadis score jumped sharply: The 2025 EcoVadis score rose to 74/100 from 66, placing Syngene in the 91st percentile globally, a material improvement in a metric that matters to large-pharma procurement teams.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Annual revenue guidance | Maintain existing FY26 revenue guidance | FY26 full year |
| EBITDA and PAT margin guidance | Maintain existing FY26 EBITDA and PAT margin guidance | FY26 full year |
| Bayview facility operationalization | Revalidation, integration and staff recruitment progressing toward operational start | H2 FY26 |
| ADC manufacturing capability | New GMP bioconjugation suite under construction in Bengaluru biologics facility | No date given |
| Peptide and ADC platform investment | Dedicated facilities being built for peptides and ADCs | No date given |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹911 Cr, +2% YoY and +4% QoQ |
| Reported revenue | ₹926 Cr, +2% YoY |
| Reported EBITDA | ₹215 Cr, -18% YoY |
| Reported EBITDA margin | 23.2%, vs 28.8% in Q2 FY25 |
| EBITDA from operations | 199.6 crore, -18.5% YoY; margin 21.9%, -556 bps YoY |
| EBIT from operations | 83 crore, -38.0% YoY; margin 9.1%, -591 bps YoY |
| Reported PAT (before exceptional items) | ₹67 Cr, -37% YoY; margin 7.3% |
| PAT | 67.1 crore, -36.7% YoY; margin 7.3%, -444 bps YoY |
| Staff costs | 307.5 crore, 33.8% of revenue from operations, -331 bps YoY |
| Foreign exchange fluctuation loss, net | 11.8 crore, vs gain of 4.3 crore in Q2 FY25 |
| Depreciation and amortisation | 116.5 crore, +5.1% YoY |
| Finance costs | 13.2 crore, +0.4% YoY |
| H1 FY26 revenue from operations | ₹1,785 Cr, +6% YoY |
| H1 FY26 reported EBITDA margin | 24.1%, vs 26.2% in H1 FY25 |
| H1 FY26 reported PAT (before exceptional items) | ₹154 Cr, -4% YoY; margin 8.5% |
| Full-year FY26 revenue guidance | Maintained |
| Full-year FY26 EBITDA and PAT margin guidance | Maintained |
| Unrecoverable receivables written off | ₹27.7 Cr net (₹20.2 Cr after tax), due to cumulative FX rate changes |
| Capitalised biologics manufacturing assets (Unit 3) | ₹343.8 Cr, resulting in additional depreciation of ₹7 Cr in Q2 FY26 |